PWMG
BLTE

Prestige Wealth Management Group’s Belite Bio BLTE Stock Holding History

Prestige Wealth Management Group’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-200
Closed -$7K – 1153
2022
Q3 		$7K Hold
200
– – ﹤0.01% 475
2022
Q2 		$6K Buy
+200
New +$3.75K ﹤0.01% 523

Other funds holding BLTE

AWS
Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Prestige Wealth Management Group's BLTE Position: Q4 2022 in Review

Prestige Wealth Management Group sold out of Belite Bio (BLTE) in Q4 2022, closing a stake of 200 shares — an estimated $7K sold.

Prestige Wealth Management Group first reported a position in BLTE in Q2 2022 and held it in 2 quarters. The position peaked at $7K in Q3 2022. 7 funds tracked by Wall St. Rank hold BLTE as of Q4 2022.

  • Prestige Wealth Management Group reported no remaining Belite Bio position as of Q4 2022 after selling out during the quarter.
  • Prestige Wealth Management Group sold 200 Belite Bio shares in Q4 2022, an estimated $7K.
  • Prestige Wealth Management Group first reported a position in Belite Bio in Q2 2022 and held it in 2 quarters.
  • Prestige Wealth Management Group's Belite Bio position peaked at $7K in Q3 2022.
  • 7 funds tracked by Wall St. Rank held Belite Bio as of Q4 2022.

Based on Prestige Wealth Management Group's 13F filing for Q4 2022, filed 8 Feb 2023.